Every AXLRx COPD report, across 4 report types. Each is scoped to your asset and verified to a live source.
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk.
Ensifentrine and dupilumab, both approved in 2024, already own the exacerbator add-on tier. A new entrant must clear a 31-41% exacerbation-reduction bar and pick a phenotype-agnostic or eosinophil-gated lane before it competes on anything else.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, and Launch Readiness for Chronic Obstructive Pulmonary Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current COPD coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest COPD reports were updated July 2026.